The EU has fined Illumina more than $400 million for proceeding with its acquisition of cancer-test developer Grail before the bloc’s antitrust watchdog had decided whether to approve the deal
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.
https://www.wsj.com/articles/illumina-fined-more-than-400-million-in-europe-for-closing-grail-deal-early-c06a10be
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Illumina Fined More Than $400 Million in Europe for Closing Grail Deal EarlyBy Kim Mackrael BRUSSELS--The European Union has fined Illumina more than $400 million for proceeding with its acquisition of cancer-test developer Grail...
Weiterlesen »
Illumina to face record EU antitrust fine for Grail deal, source saysU.S. genetic testing company Illumina will face a record EU antitrust fine on Wednesday for closing its takeover of Grail before it secured approval from EU regulators, a person familiar with the matter said on Tuesday.
Weiterlesen »
Illumina hit with record fine for closing Grail deal without EU regulatory approvalThe European Commission last year blocked Illumina's $7.1 billion acquisition of Grail over concerns it would stifle innovation and consumer choice.
Weiterlesen »
Samsung's Galaxy Tab S8 and Tab S8+ see major Prime Day discounts of $400Samsung's ultra-high-end Galaxy Tab S8 and Galaxy Tab S8+ are available at amazing Prime Day discounts of up to $250 and $400 respectively right now on Amazon.
Weiterlesen »
Prime Day 2023 Deals on Amazon Devices: Get a $400 TV for $99 and Save on Kindles, Fire Tablets, and More - E! OnlineMake your life easier with major deals on Alexa devices, Fire TV Sticks, and more great tech products.
Weiterlesen »